Future paradigms for precision oncology

Giannoula Lakka Klement, Knarik Arkun, Dalibor Valik, Tina Roffidal, Ali Hashemi, Christos Klement, Paolo Carmassi, Edward Rietman, Ondrej Slaby, Pavel Mazanek, Peter Mudry, Gabor Kovacs, Csongor Kiss, Koen Norga, Dobrin Konstantinov, Nicolas André, Irene Slavc, Henk van Den Berg, Alexandra Kolenova, Leos KrenJiri Tuma, Jarmila Skotakova, Jaroslav Sterba

Research output: Contribution to journalReview article

11 Citations (Scopus)


Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral and intra-tumoral variability. Individual tumors have unique profiles, and these molecular signatures make the use of traditional histology-based treatments problematic. The conventional diagnostic categories, while necessary for care, thwart the use of molecular information for treatment as molecular characteristics cross tissue types. This is compounded by the struggle to keep abreast the scientific advances made in all fields of science, and by the enormous challenge to organize, cross-reference, and apply molecular data for patient benefit. In order to supplement the site-specific, histology-driven diagnosis with genomic, proteomic and metabolomics information, a paradigm shift in diagnosis and treatment of patients is required. While most physicians are open and keen to use the emerging data for therapy, even those versed in molecular therapeutics are overwhelmed with the amount of available data. It is not surprising that even though The Human Genome Project was completed thirteen years ago, our patients have not benefited from the information. Physicians cannot, and should not be asked to process the gigabytes of genomic and proteomic information on their own in order to provide patients with safe therapies. The following consensus summary identifies the needed for practice changes, proposes potential solutions to the present crisis of informational overload, suggests ways of providing physicians with the tools necessary for interpreting patient specific molecular profiles, and facilitates the implementation of quantitative precision medicine. It also provides two case studies where this approach has been used.

Original languageEnglish
Pages (from-to)46813-46831
Number of pages19
Issue number29
Publication statusPublished - Jan 1 2016



  • Genomics
  • Metronomic chemotherapy
  • Precision medicine
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Klement, G. L., Arkun, K., Valik, D., Roffidal, T., Hashemi, A., Klement, C., Carmassi, P., Rietman, E., Slaby, O., Mazanek, P., Mudry, P., Kovacs, G., Kiss, C., Norga, K., Konstantinov, D., André, N., Slavc, I., van Den Berg, H., Kolenova, A., ... Sterba, J. (2016). Future paradigms for precision oncology. Oncotarget, 7(29), 46813-46831. https://doi.org/10.18632/oncotarget.9488